Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017 (2017), Article ID 7909407, 10 pages
https://doi.org/10.1155/2017/7909407
Research Article

Decreased Helios Expression in Regulatory T Cells in Acute Coronary Syndrome

1Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2Department of Geriatrics, Li Yuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, 39 Yanhu Avenue, Wuhan 430077, China

Correspondence should be addressed to Yudong Peng; moc.361@nillicinep-ma and Longxian Cheng; moc.anis@naixgnolgnehc

Received 9 June 2017; Revised 29 July 2017; Accepted 7 September 2017; Published 12 November 2017

Academic Editor: Dennis W. T. Nilsen

Copyright © 2017 Lili Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., “Heart disease and stroke statistics—2015 update: a report from the American Heart Association,” Circulation, vol. 131, no. 4, pp. e29–e322, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. G. K. Hansson, “Inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1685–1695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. K. A. Campbell, M. J. Lipinski, A. C. Doran, M. D. Skaflen, V. Fuster, and C. A. McNamara, “Lymphocytes and the adventitial immune response in atherosclerosis,” Circulation Research, vol. 110, no. 6, pp. 889–900, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Grandoch, K. Feldmann, J. R. Gothert et al., “Deficiency in lymphotoxin beta receptor protects from atherosclerosis in apoE-deficient mice,” Circulation Research, vol. 116, no. 8, pp. e57–e68, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Sakaguchi, M. Miyara, C. M. Costantino, and D. A. Hafler, “FOXP3+ regulatory T cells in the human immune system,” Nature Reviews Immunology, vol. 10, no. 7, pp. 490–500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Jozwicki, A. A. Brozyna, J. Siekiera, and A. T. Slominski, “Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal,” Oncotarget, vol. 7, no. 10, pp. 11450–11462, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Garg, J. R. Tyler, J. H. Yang et al., “Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function,” Journal of Immunology, vol. 188, no. 9, pp. 4644–4653, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Trojan, L. Zhu, M. Aly et al., “Association of peripheral NK cell counts with Helios+ IFN-γ Tregs in patients with good long-term renal allograft function,” Clinical and Experimental Immunology, vol. 188, no. 3, pp. 467–479, 2017. View at Publisher · View at Google Scholar
  9. M. Miyara, G. Gorochov, M. Ehrenstein, L. Musset, S. Sakaguchi, and Z. Amoura, “Human FoxP3+ regulatory T cells in systemic autoimmune diseases,” Autoimmunity Reviews, vol. 10, no. 12, pp. 744–755, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. George, “Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis,” Nature Clinical Practice Cardiovascular Medicine, vol. 5, no. 9, pp. 531–540, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Hasib, A. K. Lundberg, H. Zachrisson, J. Ernerudh, and L. Jonasson, “Functional and homeostatic defects of regulatory T cells in patients with coronary artery disease,” Journal of Internal Medicine, vol. 279, no. 1, pp. 63–77, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. X. Wang, C. Q. Wang, X. Y. Li, Y. Ding, G. K. Feng, and X. J. Jiang, “Changes of naturally occurring CD4+CD25+ FOXP3+ regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment,” International Heart Journal, vol. 56, no. 2, pp. 163–169, 2015. View at Publisher · View at Google Scholar
  13. E. Najib, R. Puranik, J. Duflou, Q. Xia, and S. Bao, “Age related inflammatory characteristics of coronary artery disease,” International Journal of Cardiology, vol. 154, no. 1, pp. 65–70, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Patel, S. H. Chung, G. White, S. Bao, and D. S. Celermajer, “The “atheroprotective” mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques,” International Journal of Cardiology, vol. 145, no. 2, pp. 183–187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Ammirati, D. Cianflone, M. Banfi et al., “Circulating CD4+CD25hiCD127lo regulatory T-cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 9, pp. 1832–1841, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Zhao, Y. Z. Qi, Z. Y. Yuan, M. L. Cheng, Y. Q. Ji, and X. B. Yang, “Changes of Foxp3(+); regulatory T cells in patients with acute coronary syndrome,” Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, vol. 27, no. 8, pp. 893–895, 2011. View at Google Scholar
  17. C. X. Lu, R. D. Xu, M. Cao et al., “FOXP3 demethylation as a means of identifying quantitative defects in regulatory T cells in acute coronary syndrome,” Atherosclerosis, vol. 229, no. 1, pp. 263–270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Sakaguchi, “Regulatory T cells: key controllers of immunologic self-tolerance,” Cell, vol. 101, no. 5, pp. 455–458, 2000. View at Google Scholar
  19. C. L. Bennett, J. Christie, F. Ramsdell et al., “The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3,” Nature Genetics, vol. 27, no. 1, pp. 20-21, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. M. C. Fantini, C. Becker, G. Monteleone, F. Pallone, P. R. Galle, and M. F. Neurath, “Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25 T cells through Foxp3 induction and down-regulation of Smad7,” Journal of Immunology, vol. 172, no. 9, pp. 5149–5153, 2004. View at Publisher · View at Google Scholar
  21. S. E. Allan, S. Q. Crome, N. K. Crellin et al., “Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production,” International Immunology, vol. 19, no. 4, pp. 345–354, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Q. Tran, H. Ramsey, and E. M. Shevach, “Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype,” Blood, vol. 110, no. 8, pp. 2983–2990, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. D. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” Nature Reviews Immunology, vol. 8, no. 7, pp. 523–532, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. D. Fontenot, J. P. Rasmussen, L. M. Williams, J. L. Dooley, A. G. Farr, and A. Y. Rudensky, “Regulatory T cell lineage specification by the forkhead transcription factor foxp3,” Immunity, vol. 22, no. 3, pp. 329–341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Thornton, P. E. Korty, D. Q. Tran et al., “Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells,” Journal of Immunology, vol. 184, no. 7, pp. 3433–3441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. E. M. Ross, D. Bourges, T. V. Hogan, P. A. Gleeson, and I. R. van Driel, “Helios defines T cells being driven to tolerance in the periphery and thymus,” European Journal of Immunology, vol. 44, no. 7, pp. 2048–2058, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Serre, C. Benezech, G. Desanti et al., “Helios is associated with CD4 T cells differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 expression,” PLoS One, vol. 6, no. 6, article e20731, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. R. A. Gottschalk, E. Corse, and J. P. Allison, “Expression of Helios in peripherally induced Foxp3+ regulatory T cells,” Journal of Immunology, vol. 188, no. 3, pp. 976–980, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. S. R. Daley, D. Y. Hu, and C. C. Goodnow, “Helios marks strongly autoreactive CD4+T cells in two major waves of thymic deletion distinguished by induction of PD-1 or NF-κB,” The Journal of Experimental Medicine, vol. 210, no. 2, pp. 269–285, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. H. J. Kim, R. A. Barnitz, T. Kreslavsky et al., “Stable inhibitory activity of regulatory T cells requires the transcription factor Helios,” Science, vol. 350, no. 6258, pp. 334–339, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Akimova, U. H. Beier, L. Wang, M. H. Levine, and W. W. Hancock, “Helios expression is a marker of T cell activation and proliferation,” PLoS One, vol. 6, no. 8, article e24226, 2011. View at Google Scholar
  32. C. Liu, Z. Guan, L. Zhao, Y. Song, and H. Wang, “Elevated level of circulating CD4+Helios+FoxP3+ cells in primary Sjogren’s syndrome patients,” Modern Rheumatology, pp. 1–8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Klocperk, J. Grecova, K. Sismova, J. Kayserová, E. Froňková, and A. Šedivá, “Helios expression in T-regulatory cells in patients with di George syndrome,” Journal of Clinical Immunology, vol. 34, no. 7, pp. 864–870, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Chen, M. Vander Lugt, and P. Szabolcs, “Deficiency of Foxp3/Helios co-expressing regulatory T-cells correlates with clinical acitvity in autoimmunity (HUM7P.316),” The Journal of Immunology, vol. 192, 1 Supplement, pp. 184.125–184.125, 2014. View at Google Scholar
  35. D. A. Horwitz, S. G. Zheng, J. Wang, and J. D. Gray, “Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp3+CD4+ Treg,” European Journal of Immunology, vol. 38, no. 4, pp. 912–915, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Takatori, H. Kawashima, A. Matsuki et al., “Helios enhances Treg cell function in cooperation with FoxP3,” Arthritis & Rhematology, vol. 67, no. 6, pp. 1491–1502, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. G. Wang, X. Xiong, Z. Y. Chen et al., “Expansion of myeloid-derived suppressor cells in patients with acute coronary syndrome,” Cellular Physiology and Biochemistry, vol. 35, no. 1, pp. 292–304, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Sugimoto, T. Oida, K. Hirota et al., “Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis,” International Immunology, vol. 18, no. 8, pp. 1197–1209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. M. E. Himmel, K. G. MacDonald, R. V. Garcia, T. S. Steiner, and M. K. Levings, “Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans,” Journal of Immunology, vol. 190, no. 5, pp. 2001–2008, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Khaitan, A. Kravietz, M. Mwamzuka et al., “FOXP3+Helios+ regulatory T cells, immune activation, and advancing disease in HIV-infected children,” Journal of Acquired Immune Deficiency Syndromes, vol. 72, no. 5, pp. 474–484, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Yang, X. Yuan, C. Lv et al., “Methylation of the FOXP3 upstream enhancer as a clinical indicator of defective regulatory T cells in patients with acute coronary syndrome,” American Journal of Translational Research, vol. 8, no. 12, pp. 5298–5308, 2016. View at Google Scholar
  42. E. N. Deliargyris, R. J. Raymond, T. C. Theoharides, W. S. Boucher, D. A. Tate, and G. J. Dehmer, “Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure,” The American Journal of Cardiology, vol. 86, no. 9, pp. 913–918, 2000. View at Google Scholar
  43. Y. Miyao, H. Yasue, H. Ogawa et al., “Elevated plasma interleukin-6 levels in patients with acute myocardial infarction,” American Heart Journal, vol. 126, no. 6, pp. 1299–1304, 1993. View at Google Scholar
  44. E. Lindmark, E. Diderholm, L. Wallentin, and A. Siegbahn, “Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy,” JAMA, vol. 286, no. 17, pp. 2107–2113, 2001. View at Google Scholar
  45. H. Kaji, “High-density lipoproteins and the immune system,” Journal of Lipids, vol. 2013, Article ID 684903, 8 pages, 2013. View at Publisher · View at Google Scholar
  46. F. Mahmoud and E. Al-Ozairi, “Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes,” Disease Markers, vol. 35, no. 4, pp. 235–241, 2013. View at Publisher · View at Google Scholar · View at Scopus